Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by barcodewhizon Nov 13, 2009 3:39pm
312 Views
Post# 16485382

RE: RE: RE: RE: RE: SABTO

RE: RE: RE: RE: RE: SABTO
 I have been assured over and over by IR that they have taken the criticism seriously,  and that we can expect more clarity and a better layout / update of their various initiatives.   We'll see.   I completely agree with you..

The one that kills me is Abraxis.  How can they announce a $297mm contract,  and then give ZERO updates on the progress in a year and a half.   Basically everyone is forced to effectively remove any valuation component because of the lack of clarity.  That drives me crazy

I will give credit where credit is due... Anne Leduc and Pritchard have both been very proactive and consistent in their efforts to improve... I think we are beginning to see improvements,  hope todays release takes it to an even higher standard.   The market needs clarity to value these complicated initiatives... period
Bullboard Posts